Advanced searches left 3/3

Osteoporosis - Wiley Online Library

Summarized by Plex Scholar
Last Updated: 15 June 2022

* If you want to update the article please login/register

The impact of various anti‐osteoporosis drugs on all‐cause mortality after hip fractures: A nationwide population study

"Anti--u2013osteoporosis therapy following hip fractures may reduce the overall mortality risk. " Using the Taiwan National Health Insurance Research Database, we conducted this cohort study to find patients with newly diagnosed osteoporosis and hip fractures from 2009 to 2017. A total of 45,226 new cases of osteoporotic hip fracture have been identified. Patients who did not receive any medical care, patients who had ever used oral bisphosphonates, ibandronate, zoledronic acid, and denosumab had lower all-u2010cause mortality rates than those who did not, and patients who did not receive further care, patients who had never used oral bisphosphonates, ibandronate, zoledronic acid, and denosumab had lower all-u2010cause mortality rates. Patients treated with bisphosphonates had a lower mortality risk than those treated with selective estrogen receptor modulators, according to the researchers. Patients treated with zoledronic acid had a reduced risk of mortality than those treated with oral bisphosphonates. However, patients receiving denosumab and zoledronic acid did not notice a significant decline in mortality. Different antiu2010osteoporosis drugs for surgical patients were associated with different degrees of mortality decline.

Source link: https://onlinelibrary.wiley.com/doi/10.1002/jbmr.4627


Iron overload‐induced ferroptosis of osteoblasts inhibits osteogenesis and promotes osteoporosis: An in vitro and in vivo study

"Growing reports show that iron overload is a risk factor for osteoporosis. " In vitro and in vivo, the aim of our research was to determine if iron overload may lead to ferroptosis in osteoblasts and to investigate whether osteoblast ferroptosis is involved in iron overload in vitro and in vivo. Ferric ammonium citrate was used to simulate iron overload conditions, but deferoxamine and ferrostatin u20101 were used to slow ferroptosis of MC3T3u2010E1 cells in vitro. Iron dextran was used to create a mouse iron overload model. To determine new bone formation, Enzymeu2010linked immunosorbent assays and calcination were used. In vitro, iron overload can also deter osteogenic differentiation and mineralization. These findings show that osteoblast ferroptosis plays a significant role in iron overload-induced osteoporosis in the u2010 case. Osteoporosis may be prevented by iron homeostasis and osteoblast fibroptosis.

Source link: https://onlinelibrary.wiley.com/doi/10.1002/iub.2656


Bisphosphonate Use Is Not Associated With Tuberculosis Risk Among Patients With Osteoporosis: A Nationwide Cohort Study

"We conducted a population-based cohort study by using the Taiwan National Health Insurance Research Database and the Taiwan Centers for Disease Control's TB databases. " Among 218 908 patients with osteoporosis and bone fracture, 46 842 bisphosphonate users, and 46 842 propensity scores (u2013matched nonusers) were selected. In the multivariable Cox proportional hazard model, male sex, older age, being bedridden, and steroids were not determinants of TB; however, separate risk factors, including male sex, older age, being bedridden, and steroid use, were not determinable risk factors; however, male sex, older age, being bedridden, and steroid use were not independent risk factors; According to the real world results, bisphosphonate use did not shield patients with osteoporosis against TB. ".

Source link: https://onlinelibrary.wiley.com/doi/10.1002/jcph.2090


Osteoimmunology: The correlation between osteoclasts and the Th17/Treg balance in osteoporosis

"Studies on osteoporosis and related therapy options have always been hot topics in the field of bone biology. " Osterosis research has been somewhat limited in the past; studies have only shown that osteoporosis is a result of bone resorption and bone formation, and that current studies have not provided cutting-edge theories of osteoporosis. T helper / regulatory T cells are two different types of T cells that can self-init and control differentiation and production of OCs. ".

Source link: https://onlinelibrary.wiley.com/doi/10.1111/jcmm.17399


Pregnancy Vitamin D Supplementation and Childhood Bone Mass at Age 4 Years: Findings From the Maternal Vitamin D Osteoporosis Study (MAVIDOS) Randomized Controlled Trial

"In a prospective secondary analysis by season of birth, vitamin D supplementation in pregnancy did not result in increased neonatal bone mass across the trial as a whole, but in a prespecified secondary study by season of birth, the winterborn babies had higher neonatal bone mass. " In a prespecified, single-center, randomized controlled clinical trial based in the United Kingdom, we investigated whether antenatal vitamin D supplementation raises offspring bone mineralization in early childhood. From 14 weeks of gestation to delivery, a total of 1123 women in early pregnancy were offered a baseline 25 u2010hydroxyvitamin D level 25+u2013100 nmol/L from three academic centers, with a randomized placebo or matched placebo. "In the children, maternal vitamin D supplementation resulted in higher WBLH aBMD in the children compared to placebo. ".

Source link: https://onlinelibrary.wiley.com/doi/10.1002/jbm4.10651


Automated opportunistic osteoporosis screening in routine computed tomography of the spine – comparison with dedicated quantitative CT

"The purpose of this investigation was to compare lumbar volumetric bone mineral density measured by a convolutional neural network from dedicated quantitative CT, as well as the ability of vBMD and surrogate measurements of Hounsfield units to distinguish patients with and without osteoporotic vertebral fractures in patients with and without osteoporotic vertebral fractures. For vBMD_QCT versus vBMD_OPP, a more definite match was obtained than the ICC for vBMD_QCT versus non-u2010calibrated HU vs. non-u2010calibrated HU according to an intra-u2010class correlation coefficient for vBMD_QCT versus vBMD_OPP. Osteoporosis was found in 89 patients and 88 patients, but no patient met the diagnostic criteria from normal vs. osteoporosis to osteoporosis or vice versa. Patients with vBMD_OPP demonstrated widespread VF in a subcohort of 88 patients, and 69 patients showed u22651 common VF, and discrimination between patients with and without VF was best for vBMD_OPP. ".

Source link: https://onlinelibrary.wiley.com/doi/10.1002/jbmr.4575


Morinda officinalis polysaccharide regulates rat bone mesenchymal stem cell osteogenic–adipogenic differentiation in osteoporosis by upregulating miR‐21 and activating the PI3K/AKT pathway

"Osteoporosis is a common bone metabolic disease. " Morinda officinalis polysaccharide has biological properties and medicinal potential. This review looked at the OP's mechanism. MOP stem cells from rats bone mesenchymal stem cells were pretreated with low/high amounts of MOP and subjected to osteogenic differentiation or adipogenic differentiation induction. The protein signatures of OD and AD and miRu201021 expression were found in OD and AD and miRu201021 expression. Bioinformatics and dual-u2010luciferase assay demonstrated the intended relationship between miR2021 and PTEN. MOP was used in Ovariectomy u2010-induced OP rats. BMD detectors and ELISA kits were used to determine Rat bone mineral density, serum bone metabolism indexes, and osteocalcin levels. The OD of rBMSCs was increased and AD was suspended after treatment with low/high MOP levels, and miRu201021 was increased. The effect of a high concentration of MOP on rBMSCs in miRu201021 was reversed by the knockdown. MOP has partially eliminated OP in OVX rats, according to MOP.

Source link: https://onlinelibrary.wiley.com/doi/10.1002/kjm2.12544


Nonalcoholic fatty liver disease and osteoporosis: a potential association with therapeutic implications

"NAFLD has been linked to lower bone mineral content or osteoporosis in adults in the clinical setting, but not all epidemiological studies show it. " Some of the new and emerging pharmaceutical options for NAFLD have demonstrated promising anti-u202osteoporotic activity, while others have been associated with an elevated risk of fractures and may be avoided in patients with NAFLD and concomitant osteoporosis, especially those at high risk of fractures. Some anti-u2010osteoporotic drugs may improve NAFLD, while others may adversely affect it, and, in patients with osteoporosis and NAFLD, may be avoided. If a correlation between NAFLD and osteoporosis is established, a drug targeting both disorders would be a major step forward. This review summarized the key scientific and clinical evidence on the potential relationship between NAFLD and osteoporosis, focusing on treatment concerns arising from this potential link. ".

Source link: https://onlinelibrary.wiley.com/doi/10.1111/dom.14774


The Real‐World Effect of 12 Months of Romosozumab Treatment on Patients With Osteoporosis With a High Risk of Fracture and Factors Predicting the Rate of Bone Mass Increase: A Multicenter Retrospective Study

"There are no reports on the effect of 12 months of romosozumab treatment on bone mineral density in real-u2010world clinical use because its use has only recently approved. " BMD rises and develops predictors of increase in BMD after 12 months of romosozumab therapy, according to this research. Moreover, a stepwise multiple regression analysis revealed that the TRACP u20105b value before the romosozumab administration was a significant predictor of lumbar spine BMD increases after 1 year of romosozumab administration. After 1 year of romosozumab administration, the results revealed the safety of the 12u2010month romosozumab treatment for osteoporosis with a high risk of fractures, as well as the TRACPu20105b score before romosozumab administration, which was a significant predictor of the rise in lumbar spine BMD rise after 1 year of romosozumab administration. ".

Source link: https://onlinelibrary.wiley.com/doi/10.1002/jbm4.10637


When and how to stop denosumab therapy in a patient with osteoporosis

"Denosumab is a human monoclonal antibody that selectively blocks the transcription activator of nuclear factor kappa B ligand, which regulates osteoclast function. " It is a safe treatment for osteoporosis, with reduced cumulative incidence of vertebral fractures, hip, and nonvertebral fractures as a result of an increase in bone mineral density. More research is required to establish safety and effectiveness beyond ten years of therapy, but it is likely that patients will continue to benefit from therapy beyond this. In patients with osteoporosis, we want to give you a personal view of why and how denosumab should be avoided.

Source link: https://onlinelibrary.wiley.com/doi/10.1111/cen.14747

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions